115 related articles for article (PubMed ID: 23036534)
1. Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis.
De Oliveira Gomes DC; Schwedersky RP; Barbosa De-Melo LD; Da Silva Costa Souza BL; De Matos Guedes HL; Lopes UG; Rossi-Bergmann B
Parasitology; 2012 Oct; 139(12):1562-9. PubMed ID: 23036534
[TBL] [Abstract][Full Text] [Related]
2. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
3. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice.
Gomes DC; Pinto EF; de Melo LD; Lima WP; Larraga V; Lopes UG; Rossi-Bergmann B
Vaccine; 2007 Mar; 25(12):2168-72. PubMed ID: 17240003
[TBL] [Abstract][Full Text] [Related]
4. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
[TBL] [Abstract][Full Text] [Related]
5. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
6. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with LACK-DNA promotes protective immunity in hamsters challenged with Leishmania chagasi.
DE Oliveira Gomes DC; DA Silva Costa Souza BL; DE Matos Guedes HL; Lopes UG; Rossi-Bergmann B
Parasitology; 2011 Dec; 138(14):1892-7. PubMed ID: 21867591
[TBL] [Abstract][Full Text] [Related]
9. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
11. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
12. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
Nagill R; Kaur S
Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
[TBL] [Abstract][Full Text] [Related]
13. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis.
Gomes DCO; Souza BLDSC; Schwedersky RP; Covre LP; de Matos Guedes HL; Lopes UG; Ré MI; Rossi-Bergmann B
Microbes Infect; 2022 Mar; 24(2):104884. PubMed ID: 34487860
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
16. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi.
Leal JM; Mosquini M; Covre LP; Stagmiller NP; Rodrigues RR; Christensen D; de Matos Guedes HL; Rossi-Bergmann B; Gomes DC
Parasitology; 2015 Nov; 142(13):1640-6. PubMed ID: 26394776
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.
Tewary P; Saxena S; Madhubala R
Vaccine; 2006 Mar; 24(13):2409-16. PubMed ID: 16413950
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
